Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives

Ponatinib, a third-generation tyrosine kinase inhibitor that inhibits BCR/ABL independent of the mutation status, is currently approved for the treatment of patients with chronic myeloid leukemia or acute lymphoblastic leukemia that are either resistant or unable to tolerate another tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Anagnostou, Theodora, Litzow, Mark R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467344/
https://www.ncbi.nlm.nih.gov/pubmed/31360088
http://dx.doi.org/10.2147/BLCTT.S130197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467344/
https://www.ncbi.nlm.nih.gov/pubmed/31360088
http://dx.doi.org/10.2147/BLCTT.S130197

Ejemplares similares